SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 441.28 |
| Enterprise Value ($M) | 342.01 |
| Book Value ($M) | 169.44 |
| Book Value / Share | 2.37 |
| Price / Book | 2.60 |
| NCAV ($M) | 154.77 |
| NCAV / Share | 2.17 |
| Price / NCAV | 2.85 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.50 |
| Return on Assets (ROA) | 0.54 |
| Return on Equity (ROE) | 0.69 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.32 |
| Current Ratio | 8.10 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 180.69 |
| Assets | 195.35 |
| Liabilities | 25.91 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | BlackRock, Inc. | 5.60 | 0.00 | |
| 13G | Lewis John Latane IV |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 76,834 | 446,234 | 17.22 | |
| 92,087 | 482,988 | 19.07 | |
| 114,543 | 692,150 | 16.55 | |
| 108,570 | 520,561 | 20.86 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SAGE – Sage Therapeutics, Inc. | SCYX – SCYNEXIS, Inc. |
| SGMT – Sagimet Biosciences Inc. | SKYE – Skye Bioscience, Inc. |
| SMMT – Summit Therapeutics Inc. |
Financial data and stock pages provided by
Fintel.io